Loading...
•
Sep 30, 2022
Bicycle Q3 2022 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Bicycle Therapeutics reported continued clinical progress across its pipeline and a strong balance sheet, supported by a $10 million option fee from Genentech. The company expects its financial runway to extend into 2025.
Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update.
Completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4.
BT8009 clinical update remains on-track for Q4.
Received $10 million option fee payment from Genentech this quarter.
Forward Guidance
Bicycle Therapeutics anticipates continued advancement of its product candidates, dosing in and progression of its clinical trials, and expansion of its discovery efforts and early development pipeline, with an expected financial runway into 2025.
Positive Outlook
- Advancement of product candidates BT5528, BT8009 and BT7480
- Dosing in and progression of clinical trials
- Availability and timing of announcement of data from clinical trials
- Therapeutic potential for Bicycles in oncology and other applications
- Plans to expand discovery efforts and early development pipeline
Challenges Ahead
- Risks to clinical trial site initiation, patient enrollment and follow-up due to the ongoing COVID-19 pandemic
- Uncertainties inherent in the initiation and completion of clinical trials and clinical development of product candidates
- Risk that Bicycle may not realize the intended benefits of its technology
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...